We are ready and waiting, looking forward to its final opening and to embrace the students that will walk through its doors' ...

The Government is set to mark an important milestone in rail renationalisation plans when South Western Railways is brought ...

A boarded-up Gloucester city centre pub may reopen as a food and drink establishment with the aim of “lifting the ambiance” ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, compared to placebo.Although ...

While IL2 LD is not currently licensed for MND/ALS treatment ... and logistical support from WGK Ltd and ICON plc. The clinical trial involved seven MND/ALS Centres in the UK (six in England, one in ...

Share Repurchases: $250 million at an average price of $184 per share. Icon PLC (NASDAQ:ICLR) reported better-than-expected adjusted EBITDA margin performance of 19.5% for Q1 2025, demonstrating ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported first-quarter earnings of $154.2 million. The Dublin 18, Ireland-based company said it had profit of $1.90 per share. Earnings ...